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Purpose. To evaluate anatomical retinal changes measured by spectral-domain optical coherence tomography (SD-OCT), after
applying photodynamic therapy (PDT) for treatment of chronic central serous chorioretinopathy (CSC). Methods. A
retrospective analysis was conducted on 43 patients (48 eyes) with chronic CSC treated with PDT. Visual acuity (VA), central
retinal thickness (CRT), outer nuclear layer (ONL) thickness, subretinal fluid (SRF), and photoreceptor ellipsoid zone (EZ)
measured by SD-OCT were collected at baseline and at 3, 6, and 12 months after PDT. Differences between normally
distributed variables were calculated by a paired-sample t-test; p < 0 05 was considered statistically significant. Results. Mean age
was 50± 9.8 years. Mean time from diagnosis to PDT was 12.5 months. Baseline VA was 0.51± 0.24 and significantly improved
(p < 0 001) to 0.74± 0.26 one year after PDT. CRT and SRF significantly decreased (p < 0 001) at 3, 6, and 12 months after
treatment. ONL thickness and EZ did not significantly change at any point during follow-up. Conclusions. Not significant
changes were found in the ONL or EZ 12 months after PDT.
1. Introduction
Central serous chorioretinopathy (CSC) is characterized by
the development of one or more well-circumscribed, neuro-
sensorial retinal detachments commonly associated with
serous pigment epithelial detachments (PEDs) and tends
to affect the retina at the macular area. The pathophysiology
is not completely understood, but the hallmarks of this
condition include choroidal hyperpermeability and defi-
cient pumping functions at the level of the retinal pigment
epithelium (RPE) [1, 2].
CSC is the fourth most frequent retinal pathology after
age-related macular degeneration (AMD), diabetic retinopa-
thy, and retinal vein occlusion [3, 4]. It occurs primarily in
healthy men between 25 and 55 years of age [5]. Symptoms
included decreased visual acuity (VA) and color vision,
micropsia, metamorphopsia, or paracentral scotoma. It is
related to type A personality, stress, and patients with an
elevated level of corticosteroids [6].
The natural course of acute CSC is usually excellent; most
patients (80–90%) undergo spontaneous resolution of sub-
retinal fluid (SRF) within six months. However, some
patients suffer from chronic CSC, causing permanently
diminished VA, and many (40–50%) experience one or more
recurrences. Verteporfin (Visudyne; Novartis, Basel, Switzer-
land) ocular photodynamic therapy (PDT) has been proven
off-label as an effective treatment to resolve chronic CSC,
improving VA and reabsorbing the SRF [7].
PDT has been widely used in treating wet AMD [8–10].
Serious ocular adverse events are uncommon and include
decrease in vision, secondary choroidal neovascularization
(CNV), RPE tears, and choroidal nonperfusion. Systemic
photosensitivity reactions have been reported as well, usually
occurring within 24 hours of verteporfin infusion. Patients
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are advised to avoid sun exposure and use protective clothing
for the first 2 days after treatment.
The purpose of the present study was to evaluate ana-
tomical retinal changes measured by spectral-domain optical
coherence tomography (SD-OCT), after applying PDT for
treatment of chronic CSC.
2. Methods
We retrospectively identified 75 patients with chronic CSC
treated with PDT. All patients were examined at the Depart-
ment of Ophthalmology, Miguel Servet University Hospital.
The design of the study followed the tenets of the Declaration
of Helsinki, and the protocol was approved by the Clinical
Research Ethics Committee of Aragon.
Subjects were eligible if they were adults with a diagnosis
of chronic CSC (defined as persistence of SRF for more than
3 months) with a follow-up of at least 12 months. Exclusion
criteria included opacity of the optical media that could inter-
fere with the quality of the SD-OCT; pre-existing retinal,
choroidal, or optic nerve pathology; and previous ocular
treatment with focal laser or intravitreal agents.
A full ophthalmologic examination was performed in all
patients including clinical history, best-corrected visual
acuity (BCVA, decimal scale), examination of the anterior
segment using a slit lamp, Goldmann applanation tonome-
try, ophthalmoscopy of the posterior segment, intravenous
fluorescein angiography, and SD-OCT.
All patients received full standard dose of verteporfin
(6mg/m2), which was infused over 10 minutes, followed
by laser treatment 5 minutes after. Laser was applied to
the area of hyperpermeability that was detected during
IVFA. The total light energy was 50 J/cm2 and irradiance
of 600mW/cm2 of 689 nm light over 83 s.
All eyes were scanned by the SD Cirrus OCT system (Carl
Zeiss Meditec, Dublin, California; macular cube 512× 128
scan and HD 5-line raster; software version 6.2) after
mydriasis (0.5% tropicamide; Alcon Laboratories Inc., Fort
Worth, Texas). All scans had signal strength of at least 7.
Full thickness of the outer nuclear layer (ONL), photo-
receptor ellipsoid zone (EZ; distance between the lower
border of the external limiting membrane and the anterior
surface of the RPE), SRF, and central retinal thickness (CRT)
were manually drawn at the subfoveal point by 2 retinal
specialists (J.L. and O.R.) who were blind to all clinical infor-
mation using the built-in caliper function of the Cirrus OCT.
To obtain the anatomical measurements, the HD 5-line
raster scan was used. It consists of 4096 A-scans in each
of the five lines, centered on the fovea. CRT was obtained
manually through measuring the distance between the
inner surface of the RPE and the outer surface of the neu-
rosensory retina on the horizontal HD 5-line raster scan
centered on the fovea.
2.1. Statistical Analysis. Statistical analysis was performed
using IBM’s statistical software (SPSS version 22.0; IBM
Corporation, Somers, New York). Descriptive findings were
reported as mean± SD. All study variables were normally
distributed as verified by the Kolmogorov-Smirnov test
(K-S of 1 sample). Differences between normally distributed
variables were calculated by a paired-sample t-test; p < 05
was considered statistically significant.
To analyse the relationship between quantitative vari-
ables (BCVA, disease duration, thickness measurements,
etc.), the Pearson correlation was used.
3. Results
48 eyes of 43 chronic CSC patients were finally included.
Among the patients, 12 (28%) were women and 31 (72%)
were men, with a mean age of 50± 9.8 years (28%). Mean
duration of CSC prior to treatment was 7.6± 2.7 months.
Mean period of follow-up after PDT was 12.5 months. The
mean PDT spot area was 24.2± 10.6mm2. Mean baseline
BCVA was 0.51 (20/40)± 0.24, and mean baseline CRT was
313.6± 86.6 μm. Clinical characteristics are shown in Table 1.
Table 1: Clinical characteristics of the studied sample.
Mean SD
Age (years) 50.31 9.81
Male, n (%) 31 (72%) NA
PDT spot area (mm2) 24.28 10.66
BCVA (Snellen) 0.51 (20/40) 0.24
CRT (μm) 313.63 86.63
PDT: photodynamic therapy; BCVA: best-corrected visual acuity; CRT:
central retinal thickness.
Figure 1: SD-OCT showing SRF resolution after PDT treatment.
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After initial PDT, absorption of SRF (Figure 1) was
complete in 39 eyes (81.2%); six more eyes (12.5%)
resolved after additional PDT. Two eyes (4.2%) did not
show response after third PDT, and one eye (2.1%) was
not treated because the patient refused further treatment.
No patients developed systemic or ocular adverse events
related to PDT.
3.1. SD-OCT Changes.Mean CRT at baseline and at 3, 6, and
12 months after PDT was 313.63± 86.63, 183.79, 189.44, and
177.59, respectively. ONL, SRF, and EZ thicknesses are
summarized in Table 2. After PDT, CRT and SRF became
significantly thinner at 3, 6, and 12 months (all p < 0 001).
ONL and EZ did not show significant differences during
the follow-up.
The mean BCVA at baseline and at 3, 6, and 12
months after PDT was 0.51 (20/40)± 0.24, 0.7± 0.3, 0.67
(20/30)± 0.24, and 0.74 (20/25)± 0.26, respectively. Base-
line BCVA significantly improved at 3, 6, and 12 months
after PDT (all p < 0 001).
A strong correlation was found between visual acuity
(VA) at baseline, 3 months (R = 0 747; p = 0 001), and 6
months (R = 0 720; p = 0 001). Final VA (12 months)
was inversely related with disease duration (R = −0 397;
p = 0 015). A negative relation was also found between
disease duration and ONL thickness at 12 months after
PDT (R = −0 415; p = 0 011).
4. Discussion
PDT is an effective treatment to resolve chronic CSC,
achieving anatomical response in almost 96% of the cases
and improving VA in 75%. Similar results have been pre-
viously published [7, 11–14]. Our study showed that after
initial PDT, absorption of SRF was complete in 39 eyes
(81.2%). Fujita et al. [15] studied 204 eyes with chronic
CSC and reported 182 eyes (89%) with resolution of SRF
at 12 months after half-dose PDT. Regarding VA, our
study found a significant increase in vision after PDT
treatment. Moreover, the obtained data indicated a negative
correlation of final VA (12 months) with disease duration
(R = −0 397; p = 0 015). Additionally, a positive correlation
was found between baseline VA and at 3 months (R = 0 747;
p = 0 001) and 6 months (R = 0 720; p = 0 001).
To our knowledge, this is the first study measuring
specific retinal layers after using full-fluence PDT in
chronic CSC. Although some authors have reported ocular
complications such as choroidal ischemia, RPE atrophy, or
secondary CNV using conventional dosage of PDT [16],
its use is widely extended in daily practice and is considered
a safe procedure. 12 months after PDT, we did not find
significant changes at the level of the ONL thickness or EZ
measured with SD-OCT. CSC primarily alters the outer seg-
ment. Thinning of the ONL and poor VA at baseline have
been correlated with worse outcomes [17, 18]. Since mean
disease duration was relatively short in this sample (1.5
years), we hypothesized that longer disease duration also
matched with these two features.
Silva et al. [19] evaluated in 2013 the safety and efficacy of
PDT at 48 months in 42 chronic CSC patients (46 eyes). Stra-
tus 3 OCT (time-domain) was performed to measure SRF,
neural retina thickness (NRT), and CRT. They found a com-
plete resolution of SRF in 93.4% of the eyes and a significant
decrease of CRT, but NRT remained stable during the 48
months of follow-up. The retinal atrophy was associated
with the disease itself but not related to PDT treatment.
They also reported a significant improvement in vision in
74% of the eyes.
Vasconcelos et al. [20] also published the anatomical
changes 5 years after standard PDT for chronic CSC. They
included 15 patients (17 eyes), and they also used Stratus
OCT. They also concluded that the morphological and func-
tional chorioretinal changes observed 5 years after PDT were
more related to the chronic disease than with the treatment
provided. Their CRT significantly decreased, but their NRT
remained stable.
Using SD-OCT, 4 years later, we were able to measure
specific layers, and our findings showed that the mean ONL
thickness did not differ significantly from that before PDT;
however, ONL thickness was inversely related with disease
duration (R = −0 415; p = 0 011).
Matsumoto et al. [21] investigated the ONL thickness
and EZ in 20 CSC eyes and 10 controls on Fourier domain
(FD) OCT. They found elongation of photoreceptor outer
segments and decreased ONL thickness in CSC (without
any treatment). Significant thinning of the ONL (median,
75 μm) compared with that of the normal eyes (median,
153 μm) suggests that apoptosis of the photoreceptors occurs
in the detached retina. Our findings support that PDT did
not significantly change ONL thickness. It is already
diminished because of the disease itself.
Regarding EZ, there is conflicting evidence about the
influence of PDT on photoreceptors. Previous histopatho-
logical studies reported that 1 week after PDT, Schlötzer-
Schrehardt et al. [22] did not find RPE or neurosensory
retina damage. On the other hand, recent OCT studies [23]
Table 2: Comparison of SD-OCT measurements after PDT treatment.
Baseline 3 months 6 months 12 months
CRT (μm) A 313.63± 86.63 183.79± 47.05∗ 189.44± 51.67∗ 177.59± 29.65∗
ONL (μm) B 81.43± 17.26 85.94± 18.63 80.56± 19.81 83.68± 20.87
SRF (μm) C 151.74± 87.15 8.49± 37.15∗ 20.87± 55.26∗ 1.61± 9.67∗
EZ (μm) D 81.33± 36.88 77.31± 28.11 85.71± 12.7 81.67± 28.01
∗P < 0 001. CRT: central retinal thickness; ONL: outer nuclear layer; SRF: subretinal fluid; EZ: ellipsoid zone.
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have suggested that a temporal change of photoreceptors was
found in patients treated with PDT, but their measurements
were taken outside the fovea.
This retrospective study has several limitations. The
sample size was relatively small, and the follow-up period
(12 months) was relatively short. We did not evaluate
additional useful functional retina tests as visual field or
multifocal electroretinography. Choroidal thickness (CT)
was not evaluated because data regarding axial length and
refraction were not available. OCT scans were performed at
different times in each patient, which also affects CT. Treat-
ment location was not registered, and retinal measurements
were only made at the subfoveal area. There is the need for
further studies to ascertain the relationship between changes
in ONL layer and EZ and the long-term risk of retinal toxicity
with PDT treatment.
In conclusion, this study indicated that ONL and EZ did
not decrease thickness in chronic CSC patients 12 months
after PDT therapy, using SD-OCT.
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